American Shared Hospital Services vs Exagen
AMS and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMS and XGN compare
Exagen is the larger company, worth 13 times as much as American Shared Hospital Services ($91.3M against $7.1M).
Exagen grew revenue faster over the last twelve months (20.8% versus 4.0% for American Shared Hospital Services).
American Shared Hospital Services keeps more of each dollar of sales as profit, with a net margin of −5.8% compared with −26.6% at Exagen.
American Shared Hospital Services scores higher on the StockData Score (7 against 5 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMS | XGN |
|---|---|---|
| Size and price | ||
| Market cap | $7.1M | $91.3M |
| Share price | $1.07 | $3.77 |
| Change, 1 year | −52.2% | −59.7% |
| Change, 5 years | −58.4% | −65.8% |
| Beta (5Y) | 0.73 | 2.77 |
| Employees | 44 | 220 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 1.3× |
| P/B | 0.3× (better) | 7.5× |
| EV/EBITDA | 10.7× | – |
| P/FCF | 2.0× | – |
| FCF yield | 49.7% (better) | −8.3% |
| Fair value | $3.00 | $3.42 |
| Margin of safety | 64.4% (better) | −10.2% |
| Growth | ||
| Revenue growth (TTM) | 4.0% | 20.8% (better) |
| Revenue growth, 5Y average | 9.5% | 9.7% (better) |
| Profitability | ||
| Gross margin | 17.1% | 58.6% (better) |
| Operating margin | −11.8% (better) | −18.6% |
| Net margin | −5.8% (better) | −26.6% |
| FCF margin | 11.6% (better) | −10.7% |
| Return on equity | −7.5% (better) | −114% |
| Return on invested capital | −8.7% (better) | −86.1% |
| Financial health | ||
| Debt / equity | 0.70 (better) | 1.87 |
| Net debt / EBITDA | 5.34 | – |
| Interest coverage | −2.7× | −2.6× (better) |
| Current ratio | 0.77 | 3.18 (better) |
| Altman Z-score | 0.48 (better) | −6.08 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.6% | 34.1% |
| Held by insiders | 38.1% | 29.2% |
| Insider net buying, 12 months | $1.3M (better) | −$769K |
| Short interest, % of float | 0.28% | 4.2% |
Go deeper
- AMS stock overview
- AMS income statement
- AMS valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.